Drugs / TP-271
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT03450187 Comparator | Mar → Dec 2018 | bacterial infectious disease | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03234738 Comparator | Aug 2017 → Jan 2018 | bacterial infectious disease | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03024034 Comparator | Mar → Dec 2017 | bacterial infectious disease | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02724085 Comparator | Dec 2015 → Sep 2016 | pneumonia | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP 271 | “single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50...” NCT03024034 ↗ |
| Modality | Small molecule | “TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens.” NCT02724085 ↗ |
| Route | Intravenous | “It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg” NCT02724085 ↗ |